Evidence map›Paper›PMID 31776732›Full record

Trial reportInternational journal of clinical oncology2020

The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Veerisa Vimolchalao, Siwat Sakdejayont, Ploytuangporn Wongchanapai, Shama Sukprakun, Pattama Angspatt, Wilai Thawinwisan, Piyachut Chenaksara, Virote Sriuranpong, Chanida Vinayanuwatikun, Napa Parinyanitikun and 2 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Global inequitable distribution of seminal studies of chemotherapy-induced nausea and vomiting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Veerisa VimolchalaoDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd., Pathumwan, Bangkok, 10330, Thailand.
Siwat SakdejayontDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd., Pathumwan, Bangkok, 10330, Thailand.
Ploytuangporn WongchanapaiDivision of Medical Oncology, Department of Internal Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Shama SukprakunOncology Section, Production Division, Pharmacy Department, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Pattama AngspattDivision of Medical Oncology, Department of Internal Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Wilai ThawinwisanDepartment of Nursing, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Piyachut ChenaksaraDepartment of Nursing, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Virote SriuranpongDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd., Pathumwan, Bangkok, 10330, Thailand.
Chanida VinayanuwatikunDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd., Pathumwan, Bangkok, 10330, Thailand.
Napa ParinyanitikunDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd., Pathumwan, Bangkok, 10330, Thailand.
Nattaya PoovorawanDivision of Medical Oncology, Department of Internal Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Suebpong TanasanvimonDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd., Pathumwan, Bangkok, 10330, Thailand. surbpong@yahoo.com.ORCID http://orcid.org/0000-0002-3904-4719
Thai Red Cross Society · THChulalongkorn University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for chemotherapy-induced nausea vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy (HEC).

methodsIn this randomized, double-blind, placebo-controlled, crossover study, we randomly assigned chemotherapy-naïve patients receiving HEC to receive olanzapine or placebo in addition to ondansetron and dexamethasone. All subjects were crossed over to another treatment arm on second-cycle chemotherapy. The primary endpoint was complete response (CR) rate defined as no vomiting and no use of rescue drugs.

resultsAt the first cycle, there were significantly more patients with CR in the olanzapine group than in the placebo group in overall phase (68.7% vs. 25.0%, p < 0.001), acute phase (0-24 h) (75.0% vs. 31.2%, p < 0.001) and delayed phase (24-120 h) (68.7% vs. 43.7%, p = 0.038). After crossover, there were significantly more patients with CR in the olanzapine group than in the placebo group in overall phase (67.2% vs. 25.0%, p < 0.001), acute phase (71.9% vs. 32.8%, p < 0.001) and delayed phase (67.2% vs. 37.5%, p < 0.001). In crossover analysis, the olanzapine group had significantly lower mean nausea (1.28 vs. 3.05, p < 0.001) and fatigue (3.5 vs. 4.58, p < 0.001) scores but higher mean appetite (2.5 vs. 1.55, p = 0.003) and sleepiness (3.26 vs. 2.2, p < 0.001) scores. There were no grade 3 and 4 anti-emetic-drug-related toxicities. Mean QT interval changes did not different between two groups (-4.30 vs. -1.86, p = 0.69).

conclusionThe addition of olanzapine to ondansetron and dexamethasone significantly improved CINV prevention and was safe in patients receiving HEC.

Indexed as

AdultAgedAntiemeticsAntineoplastic AgentsDexamethasoneDouble-Blind MethodFemaleHumansMaleMiddle AgedNauseaOlanzapineOndansetronTreatment OutcomeVomitingAntiemeticsAntineoplastic AgentsDexamethasoneOlanzapineOndansetronCINV preventionHECOlanzapineOndansetron

Identifiers

PMID31776732
OpenAlexW2989713843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.